MedTrace Logo

Dopamine and Sensorimotor Function in Stuttering

NCT07215884 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-10-14

No results posted yet for this study

Summary

This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of stuttering and possible interventions.

Conditions

  • Stuttering, Adult

Interventions

DRUG

Aripiprazole 10 MG

The effects of aripiprazole on stuttering and various behavioral and neural outcomes will be studied compared to placebo.

DRUG

Placebo

Placebo will be compared against aripiprazole for effect on stuttering and various behavioral and neural markers.

Sponsors & Collaborators

Principal Investigators

  • John Houde, PhD · University of California, San Francisco

  • Srikantan Nagarajan, PhD · University of California, San Francisco

  • Ludo Max, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07215884 on ClinicalTrials.gov